Association of lipoprotein lipase expression with TP53 gene polymorphisms in chronic lymphocytic leukemia cells


  • I. Abramenko National Research Centre for Radiation Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv 02000, Ukraine
  • N. Bilous National Research Centre for Radiation Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv 02000, Ukraine
  • A. Chumak National Research Centre for Radiation Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv 02000, Ukraine
  • I. Dyagil National Research Centre for Radiation Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv 02000, Ukraine
  • Z. Martina National Research Centre for Radiation Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv 02000, Ukraine



chronic lymphocytic leukemia, IGHV mutational status, lipoprotein lipase


Summary. Background: Expression of lipoprotein lipase (LPL) correlates with unmutated (UM) status of the variable region of the heavy chain of immunoglobulin (IGHV) genes, but the expression level of LPL in UM chronic lymphocytic leukemia (CLL) cases varies significantly. Aim: To study the association of LPL expression with the genetic variants of the TP53 gene since both genes are involved in lipid metabolism. Materials and Methods: Expression of LPL mRNA was measured in peripheral blood mononuclears of 45 CLL patients with UM IGHV genes by real-time quantitative reverse transcription polymerase chain reaction. Mutational status of IGHV genes and TP53 genotyping (rs1042522, rs1642785, rs17883323, rs2909430, rs145153611, rs113530090, rs12947788, rs12951053, and rs17878362) were performed by polymerase chain reaction amplification followed by direct sequencing. Results: Observed CLL patients were divided on groups with low (11.17 ± 2.66) and high (275.48 ± 39.37) LPL expression. In CLL patients with UM IGHV genes and low LPL expression we found an increased frequency of rs1042522 G (p = 0.0036), rs1642785 C (p = 0.0001), and rs17878362A2 alleles (p = 0.0091). The possible functional significance of these changes is discussed. Conclusion: Some polymorphic variants of TP53 may be genetic modifiers for LPL expression level in CLL leukemic B-cells. Further research is required in a larger cohort to confirm these findings.


Dighiero G. Unsolved issues in CLL biology and management. Leukemia 2003; 17: 2385–91.

Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–7. PMID: 10477712.

Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–54. PMID: 10477713.

Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639–47.

Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194: 1625–38.

Prieto D, Oppezzo P. Lipoprotein lipase expression in chronic lymphocytic leukemia: new insights into leukemic progression. Molecules 2017; 22: 2083.

Abreu C, Moreno P, Palacios F, et al. Methylation status regulates lipoprotein lipase expression in chronic lymphocytic leukemia. Leuk Lymphoma 2013; 54: 1844–8.

Plesingerova H, Librova Z, Plevova K, et al. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status. Leuk Lymphoma 2017 58: 70–9.

Bilous N, Abramenko I, Chumak A, et al. Analysis of LPL gene expression in patients with chronic lymphocytic leukemia. Exp Oncol 2019; 41: 39–45. PMID: 30932419.

Vasconcelos Y, De Vos J, Vallat L, et al. Gene expression profiling of chronic lymphocytic leukemia can discriminate cases with stable disease and mutated Ig genes from those with progressive disease and unmutated Ig genes. Leukemia 2005; 19: 2002–5.

Kaderi MA, Kanduri M, Buhl AM, et al. LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia. Haematologica 2011; 96: 1153–60.

Heintel D, Kienle D, Shehata M, et al. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 1216–23.

Mansouri M, Sevov M, Fahlgren E, et al. Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity. Leuk Res 2010; 34: 301–6.

Rombout A., Verhasselt B., Philippé J. Lipoprotein lipase in chronic lymphocytic leukemia: function and prognostic implications. Eur J Haematol 2016; 97: 409–15.

Bilban M, Heintel D, Scharl T, et al. Deregulated expression of fat and muscle genes in B- cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia 2006; 20: 1080–8.

Rozovski U, Grgurevic S, Bueso-Ramos C, et al. Aberrant LPL expression, driven by STAT3, mediates free fatty acid metabolism in CLL cells. Mol Cancer Res 2015; 13: 944–53.

McCaw L, Shi Y, Wang G, et al. Low density lipoproteins amplify cytokine-signaling in chronic lymphocytic leukemia cells. EBioMedicine 2017; 15: 24–35.

Berkers CR, Maddocks OD, Cheung EC, et al. Metabolic regulation by p53 family members. Cell Metab 2013; 18: 617–33.

Kruiswijk F, Labuschagne CF, Vousden KH. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol 2015; 16: 393–405.

Napoli M, Flores ER. The p53 family orchestrates the regulation of metabolism: physiological regulation and implications for cancer therapy. Br J Cancer 2017; 116: 149–155.

Labuschagne CF, Zani F, Vousden KH. Control of metabolism by p53 — cancer and beyond. Biochim Biophys Acta Rev Cancer 2018; 1870: 32–42.

Hallek M, Cheson DD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood 2008; 111: 5446–56.

Abramenko I, Bilous N, Chumak A, et al. Chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chernobyl NPP accident — with focus on immunoglobulin heavy chain gene analysis. Leuk Res 2008; 32: 535–42.

Van Bockstaele F, Pede V, Janssens A, et al. Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia. Clin Chem 2007; 53: 204–12.

Bilous N, Abramenko I, Saenko V, et al. Clinical relevance of TP53 polymorphic genetic variations in chronic lymphocytic leukemia. Leuk Res 2017; 58: 1–8.

Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9: 749–58.

Hamadou WS, Besbes S, Bourdon V, et al. Mutational analysis of TP53 gene in Tunisian familial hematological malignancies and sporadic acute leukemia cases. Fam Cancer 2017; 16: 153–7.

Greathouse KL, White JR, Vargas AJ, et al. Interaction between microbiome and TP53 in human lung cancer. Genome Biol 2018; 19: 123.

Han PZ, Cao DH, Zhang XL, et al. Association between TP53 gene codon72 polymorphism and prostate cancer risk: a systematic review and meta-analysis. Medicine (Baltimore) 2019; 98: e16135.

Kratz CP, Achatz MI, Brugières L, et al. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res 2017; 23: e38–e45.

Naccarati A, Polakova V, Pardini B, et al. Mutations and polymorphisms in TP53 gene — an overview on the role in colorectal cancer. Mutagenesis 2012; 27: 211–8.

Ramasamy I. Update on the molecular biology of dyslipidemias. Clin Chim Acta 2016; 454: 143–85.

Sabir JSM, El Omri A, Shaik NA, et al. The genetic association study of TP53 polymorphisms in Saudi obese patients. Saudi J Biol Sci 2019; 26: 1338–43.

Omrani-Nava V, Hedayatizadeh-Omran A, Alizadeh-Navaei R, et al. TP53 single nucleotide polymorphism (rs1042522) in Іranian patients with coronary artery disease. Biomed Rep 2018; 9: 259–65.

Gloria-Bottini F, Saccucci P, Magrini A, et al. p53 Codon 72 polymorphism and coronary artery disease: evidence of association with left ventricular ejection fraction. Am J Med Sci 2012; 343: 127–30.

Burgdorf KS, Grarup N, Justesen JM, et al. Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans. PLoS One 2011; 6: e15813.

Gaulton KJ, Willer CJ, Li Y, et al. Comprehensive association study of type 2 diabetes and related quantitative traits with 222 candidate genes. Diabetes 2008; 57: 3136–44.

Marcel V, Tran PL, Sagne C, et al. G-quadruplex structures in TP53 intron 3: role in alternative splicing and in production of p53 mRNA isoforms. Carcinogenesis 2011; 32: 271–8.

Perriaud L, Marcel V, Sagne C, et al. Impact of G-quadruplex structures and intronic polymorphisms rs17878362 and rs1642785 on basal and ionizing radiation-induced expression of alternative p53 transcripts. Carcinogenesis 2014; 35: 2706–15.

Morten BC, Wong-Brown MW, Scott RJ, Avery-Kiejda KA. The presence of the intron 3 16 bp duplication polymorphism of p53 (rs17878362) in breast cancer is associated with a low Δ40p53:p53 ratio and better outcome. Carcinogenesis 2016; 37: 81–6.

Courtois S, Verhaegh G, North S, et al. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 2002; 21: 6722–8.

Hafsi H, Santos-Silva D, Courtois-Cox S. Hainaut P. Effects of Δ40p53, an isoform of p53 lacking the N-terminus, on transactivation capacity of the tumor suppressor protein p53. BMC Cancer 2013; 13: e134.

Xu S, Wu W, Huang H, et al. The p53/miRNAs/Ccna2 pathway serves as a novel regulator of cellular senescence: complement of the canonical p3/p21 pathway. Aging Cell 2019; 18: e12918.

Chen T, Li Z, Tu J, et al. MicroRNA-29a regulates pro-inflammatory cytokine secretion and scavenger receptor expression by targeting LPL in oxLDL-stimulated dendritic cells. FEBS Lett 2011; 585: 657–63.




How to Cite

Abramenko, I., Bilous, N., Chumak, A., Dyagil, I., & Martina, Z. (2023). Association of lipoprotein lipase expression with TP53 gene polymorphisms in chronic lymphocytic leukemia cells. Experimental Oncology, 43(3), 224–228.



Original contributions

Most read articles by the same author(s)